Founded in 1992, CBR is entrusted by parents with storing more than
875,000 cord blood and cord tissue samples for their children. CBR is
dedicated to advancing the clinical application of cord blood and cord
tissue stem cells by partnering with institutions to establish
FDA-regulated clinical trials for conditions that have no cure today.
CBR has helped more than 500 families use their cord blood stem cells
for established and experimental medical treatments, more than any
other family cord blood bank. CBR’s goal is to expand the
potential scope of newborn stem cell therapies that may be available
to patients and their families.
CBR Cord Blood Registry is headquartered in South San Francisco,
California. CBR’s owned 80,000 square foot laboratory is located
in Tucson, Arizona.
Cord Blood Registry is a registered trademark of CBR Systems, Inc.
History of Quality
CBR maintains standards for cellular therapy services through AABB
accreditation, FDA-registration, and CLIA certification.
CBR has the longest history of accreditation with the AABB and the
company’s quality standards have been recognized through ISO
9001:2015 certification — the global business standard for
A pioneer in newborn stem cell collection and cryopreservation, CBR
believes in the power of newborn stem cells to improve lives today and
their potential to revolutionize treatment for many conditions in the
CBR is the first family newborn stem cell bank to partner with leading
research institutions to establish
FDA-regulated clinical trials
exploring the potential regenerative ability of stem cells to help
treat conditions that have no cure today, including: acquired hearing
loss, autism, cerebral palsy, and pediatric stroke. In fact, 73% of
the stem cell units released by CBR have been used for experimental
regenerative therapies – more than any other family cord blood
bank in the world.
CBR created the world’s only collection device designed
specifically for cord blood stem cells. CBR’s
contains everything the healthcare provider needs to help maximize the
cord blood collection volume.
CBR developed a crush-resistant, temperature protected, and
electronically tracked kit that actively transforms into a cube to
encase the blood and/or tissue collection, helping to ensure that it
is protected and delivered safely. On average, the
from the hospital to CBR’s lab is 19 hours. CBR processes cord
blood using the
AutoXpress® Platform* (AXP®)
— a fully automated, functionally closed stem cell processing
technology. CBR has the industry’s highest published average
cell recovery rate of 99%.1-3,8
*AXP and AutoXpress are registered trademarks of ThermoGenesis Corp